In a nuclear or radiological incident, first responders must quickly measure the radiation exposure of a large number of individuals, since treatment options are radiation dose-dependent and time-sensitive. SRI is developing a biodosimeter to meet this critical challenge.
SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.
Novel molecular targets of several cytokines are being evaluated by SRI scientists, with the goal of designing a small-molecule drug to block responses involved in many of these inflammatory diseases.
SRI has developed a breakthrough technology for diagnosing and predicting fatigue failure in pipelines, aircraft, bridges, power plants, and other structures using quantitative 3D fractography.
Through a broad range of services for the National Institutes of Health, SRI is accelerating preclinical development of potential therapies for diseases that affect millions of people.
